JP2002513386A5 - - Google Patents

Download PDF

Info

Publication number
JP2002513386A5
JP2002513386A5 JP1998511735A JP51173598A JP2002513386A5 JP 2002513386 A5 JP2002513386 A5 JP 2002513386A5 JP 1998511735 A JP1998511735 A JP 1998511735A JP 51173598 A JP51173598 A JP 51173598A JP 2002513386 A5 JP2002513386 A5 JP 2002513386A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998511735A
Other languages
English (en)
Japanese (ja)
Other versions
JP4451930B2 (ja
JP2002513386A (ja
Filing date
Publication date
Priority claimed from US08/697,815 external-priority patent/US5789395A/en
Application filed filed Critical
Publication of JP2002513386A publication Critical patent/JP2002513386A/ja
Publication of JP2002513386A5 publication Critical patent/JP2002513386A5/ja
Application granted granted Critical
Publication of JP4451930B2 publication Critical patent/JP4451930B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP51173598A 1996-08-30 1997-08-21 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法 Expired - Lifetime JP4451930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/697,815 1996-08-30
US08/697,815 US5789395A (en) 1996-08-30 1996-08-30 Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
PCT/US1997/014723 WO1998008480A2 (en) 1996-08-30 1997-08-21 Method of using tetracycline compounds for inhibition of nitric oxide production

Publications (3)

Publication Number Publication Date
JP2002513386A JP2002513386A (ja) 2002-05-08
JP2002513386A5 true JP2002513386A5 (enExample) 2005-04-07
JP4451930B2 JP4451930B2 (ja) 2010-04-14

Family

ID=24802673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51173598A Expired - Lifetime JP4451930B2 (ja) 1996-08-30 1997-08-21 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法

Country Status (8)

Country Link
US (2) US5789395A (enExample)
EP (1) EP0966525A4 (enExample)
JP (1) JP4451930B2 (enExample)
KR (1) KR100554859B1 (enExample)
AU (1) AU718234B2 (enExample)
CA (2) CA2264552C (enExample)
NZ (1) NZ334512A (enExample)
WO (1) WO1998008480A2 (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2248084A1 (en) 1996-03-04 1997-09-12 Genetrace Systems, Inc. Methods of screening nucleic acids using mass spectrometry
US6605447B2 (en) * 1996-03-15 2003-08-12 Yale University Methods and means of detecting nitric oxide synthase
US5965363A (en) 1996-09-19 1999-10-12 Genetrace Systems Inc. Methods of preparing nucleic acids for mass spectrometric analysis
CA2270132A1 (en) 1996-11-06 1998-05-14 Sequenom, Inc. Dna diagnostics based on mass spectrometry
WO1998026095A1 (en) 1996-12-10 1998-06-18 Genetrace Systems Inc. Releasable nonvolatile mass-label molecules
JP2001511151A (ja) * 1997-02-04 2001-08-07 ザ ジェネラル ホスピタル コーポレイション 表皮又は皮膚疾患部の処理方法と形質転換動物
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
AU2001599A (en) * 1997-12-19 1999-07-05 New York University Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US6277061B1 (en) * 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6455583B1 (en) * 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
PT102160B (pt) * 1998-05-26 2001-04-30 Hovione Sociedade Quimica S A Processo para a preparacao de 4-(des-dimetilamino)-tetraciclinas
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6946453B2 (en) 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
US6506740B1 (en) 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis
WO2000064479A1 (en) * 1999-04-27 2000-11-02 Antibody Systems, Inc. Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders
US6500812B2 (en) 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6849615B2 (en) 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
WO2001024781A2 (en) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same
JP2003523963A (ja) 2000-01-24 2003-08-12 トラスティーズ・オブ・タフツ・カレッジ クリプトスポリジウム・パルヴム関連疾患の治療のためのテトラサイクリン化合物
WO2001052902A1 (en) * 2000-01-24 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
GB0004531D0 (en) * 2000-02-25 2000-04-19 Richards Andrew J M The treatment of respiratory diseases
BR0109725A (pt) 2000-03-31 2003-02-04 Tufts College Composto de tetraciclina substituìdo, método para tratar um estado responsivo a tetraciclina em um mamìfero, composição farmacêutica, método para sintetizar um composto de tetraciclina 7- ou 9-substituìdo, e, intermediário reativo
US6613756B2 (en) 2000-05-05 2003-09-02 Wisconsin Alumni Research Foundation Use of tetracycline derivatives in treating multiple sclerosis
EP1286954B1 (en) * 2000-05-15 2004-04-14 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
WO2001096607A2 (en) 2000-06-13 2001-12-20 The Trustees Of Boston University Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing
AU2001268475A1 (en) * 2000-06-16 2002-01-02 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
US20020132798A1 (en) 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20040224927A1 (en) * 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
WO2002004404A2 (en) 2000-07-07 2002-01-17 Trustees Of Tufts College 7,8 and 9-substituted tetracycline compounds
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
CN1450989A (zh) * 2000-07-07 2003-10-22 塔夫茨大学信托人 7－取代的四环素化合物
US20050143353A1 (en) * 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
KR100674047B1 (ko) 2000-07-07 2007-01-25 트러스티즈 오브 터프츠 칼리지 9-치환된 미노사이클린 화합물
WO2002020022A1 (en) * 2000-09-06 2002-03-14 Neurotherapeutics, Llc Method of treating neurologic disorders
US20030021761A1 (en) * 2001-01-18 2003-01-30 Geltex Pharmaceuticals, Inc. Ionene polymers and their use in treating mucositis
US7045349B2 (en) * 2001-01-23 2006-05-16 Benedict Daniel J Method of islet isolation using process control
WO2002072506A2 (en) * 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
IL157860A0 (en) 2001-03-13 2004-03-28 Paratek Pharm Innc 7,9-substituted tetracycline compounds
JP2005504722A (ja) 2001-03-14 2005-02-17 パラテック ファーマシューティカルズ インコーポレイテッド 相乗的抗真菌薬剤としての置換テトラサイクリン化合物
CA2457234A1 (en) * 2001-03-14 2002-09-19 Mark L. Nelson Substituted tetracycline compounds as antifungal agents
AU2002303250B2 (en) * 2001-04-05 2006-05-25 Collagenex Pharmaceuticals, Inc. Methods of treating acne
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
EP1383483A4 (en) * 2001-04-05 2006-08-09 Collagenex Pharm Inc CONTROLLED RELEASE OF TETRACYCLIN COMPOUNDS AND TETRACYCLINE DERIVATIVES
CA2444899C (en) * 2001-04-24 2011-06-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
GB0114672D0 (en) * 2001-06-15 2001-08-08 Orthogenics As Pharmaceutical formulations and methods of medical treatment
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2332547A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of inflammatory bowel disease
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
EP2311798A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
US6833139B1 (en) 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
WO2003075857A2 (en) 2002-03-08 2003-09-18 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
CA2479877C (en) 2002-03-21 2012-08-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2003226112B9 (en) 2002-03-29 2008-06-05 The Research Foundation Of State University Of New York Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
NZ538198A (en) * 2002-07-12 2006-11-30 Univ New York State Res Found Method for reducing C-reactive protein (CRP) levels by administering a non-antibacterial tetracycline formulation or a low dose of an antibacterial tetracycline formulation
AU2003261161B2 (en) 2002-07-12 2009-09-10 Paratek Pharmaceuticals, Inc 3, 10, and 12a substituted tetracycline compounds
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
JP2006503898A (ja) * 2002-10-24 2006-02-02 パラテック ファーマシューティカルズ， インク． マラリア治療のための置換テトラサイクリン化合物
WO2004046109A2 (en) * 2002-11-19 2004-06-03 Genzyme Corporation Ionene oligomers and polymers
CA2521885C (en) 2003-04-07 2013-06-25 Shire Laboratories, Inc. Once daily formulations of tetracyclines
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1656341A1 (en) 2003-07-09 2006-05-17 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
DE10343887B3 (de) * 2003-09-19 2004-12-09 Goodwell International Ltd., Tortola Snowboardbindung
EP2332904A3 (en) 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
US20050176140A1 (en) * 2004-02-10 2005-08-11 Benedict Daniel J. Method and apparatus for cell culture using a two liquid phase bioreactor
TWI261038B (en) * 2004-08-11 2006-09-01 Bo-Cheng Chen Bicycle gear-shifting handgrip
EP2269978A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2301916A3 (en) 2004-10-25 2011-09-28 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20070093455A1 (en) * 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
IL270446B2 (en) 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2120963B1 (en) 2006-12-21 2018-09-12 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
AP2657A (en) * 2007-03-23 2013-05-07 Molecular Res Ct Inc Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy
EP2213655A1 (en) 2007-04-27 2010-08-04 Paratek Pharmaceuticals, Inc. Methods For Purifying Aminoalkyl Tetracycline Compounds
EA201070233A1 (ru) * 2007-07-06 2010-08-30 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
TW202332671A (zh) * 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
EP2307027A4 (en) 2008-07-11 2012-08-15 Neumedics TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
CN105367440A (zh) 2008-08-08 2016-03-02 四相制药公司 C7-氟取代的四环素化合物
KR101290745B1 (ko) 2010-06-03 2013-07-29 한국해양과학기술원 라말린을 함유하는 염증질환 또는 면역질환의 예방 또는 치료용 약학 조성물
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
HUE037852T2 (hu) 2009-08-28 2018-09-28 Tetraphase Pharmaceuticals Inc Tetraciklin-vegyületek
PL2552890T3 (pl) 2010-03-31 2017-07-31 Tetraphase Pharmaceuticals, Inc. Policykliczne związki tetracyklinowe
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
EP3574908B8 (en) 2011-05-12 2024-09-11 Almirall LLC Pharmaceutical composition for oral administration comprising crystalline salts of (4s, 4as, 5ar, 12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2carboxylic acid amide
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
EP2872146A4 (en) * 2012-07-13 2016-01-06 Paratek Pharm Innc TETRACYCLIN COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EA031523B1 (ru) 2012-08-31 2019-01-31 Тетрафейз Фармасьютикалс, Инк. Тетрациклиновые соединения
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
HRP20240605T1 (hr) 2016-10-19 2024-07-19 Tetraphase Pharmaceuticals, Inc. Kristalni oblici eravaciklina
FR3081559B1 (fr) * 2018-05-28 2020-05-08 Noptrack Procede pour detecter une pathologie par reperage d'une quantite de no produite par le sujet etudie et appareil pour la mise en œuvre dudit procede
US12570604B2 (en) 2018-11-09 2026-03-10 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a tetracycline compound and uses thereof
FR3103901B1 (fr) * 2019-11-28 2023-02-24 Noptrack Detection d’une espece chimique dans la sueur d’un sujet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478946A (en) * 1989-06-21 1995-12-26 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5358969A (en) * 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US5246970A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
CA2150125A1 (en) * 1992-11-25 1994-06-09 Timothy R. Billiar Cdna clone for human inducible nitric oxide synthase and process for preparing same
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases

Similar Documents

Publication Publication Date Title
JP2001507295A5 (enExample)
JP2000510446A5 (enExample)
JP2001502505A5 (enExample)
JP2000504593A5 (enExample)
JP2001503295A5 (enExample)
JP2002513386A5 (enExample)
JP2000514307A5 (enExample)
JP2000515006A5 (enExample)
JP2000516761A5 (enExample)
JP2000508920A5 (enExample)
JP2000508477A5 (enExample)
JP2000509289A5 (enExample)
JP2001503506A5 (enExample)
JP2000513247A5 (enExample)
JP2001502734A5 (enExample)
JP2000506046A5 (enExample)
JP2001502854A5 (enExample)
JP2000516162A5 (enExample)
JP2001507002A5 (enExample)
JP2001507792A5 (enExample)
JP2002513466A5 (enExample)
JP2001502609A5 (enExample)
JP2001527382A5 (enExample)
JP2001506915A5 (enExample)
JP2001505234A5 (enExample)